Nine Ann Medical performance face was ordered rectification company said due to poor communication

Wearable concept leading stock nine health care (002432, closing price of 19.58 Yuan) the performance of the face caused by regulatory attention. Yesterday (May 15), the nine Health Medical Bulletin said, received the Shenzhen stock Supervision letter, Shenzhen, the company's performance before and after the data there is a large difference in violation of the relevant regulations, ordered the company to the relevant responsible person to propose corrective action. Affected by this, the nine health care shares plunged 8.5% on the day. The company said that because of the business communication is not smooth Shenzhen securities Regulatory letter pointed out: The February 28, 2014 and April 15, respectively, the disclosure of the 2013 annual performance Letters and 2013 performance Letters Revised bulletin, the performance data there is a big difference in violation of the Shenzhen Stock Exchange "stock listing rules" of the relevant provisions. "Daily economic news" earlier reported that February 28 nine health care released performance letters are expected to achieve 2013 operating income of 429 million yuan, net profit of 5.798 million yuan; however, the April 15 performance Express revised announcement, but the operating income was reduced to 408 million yuan, revised year-on-year growth of 14.66%, Net profit attributable to 8.3089 million yuan, a sharp decline of 219.49%. The regulatory letter points out that the absolute amount of net profit varies greatly between the two and violates the provisions of articles 2.1 and 11th 3.7 of the stock listing rules of the Shenzhen Stock Exchange. In this respect, the nine health care in the announcement that due to the company's current branches, especially the overseas branches more, the company has only in recent years to promote the independent brand in overseas marketing sales model, both in the overseas marketing ability, management ability need to constantly explore the accumulation of domestic and foreign companies in the financial coordination between the management of the work is not perfect. In addition, because the European companies are newly established companies, currently commissioned by the third party bookkeeping, in the early communication process, due to language, work habits of different, business communication is not very smooth. After the announcement of the previous performance letters, the company's financial departments still devote a lot of energy to the financial report on the various business repeatedly verified, fixed some existing problems. According to the requirements of the exchange, JIU ' an medical treatment proposed the corresponding rectification measures: the responsible personnel for the warning disciplinary, suspended 2013 annual award, ordered to correct and review. By this effect, yesterday nine health care shares plunged, down 8.5% to close, closed at 19.58 Yuan. Smart watch performance contribution limited nine medical securities representative Zi to the daily economic news reporter, after the performance Express revised, many investors also called, said that the performance correction on the company's share price impact, the impact on their investment is very large. "In this respect, we will strengthen the financial management, internal management, hope that the disclosure of information can accurately reflect the company's situation." "The reporter noted that the company released last August, the first ihealth can wear health smart watch, including brokers, funds, and many other institutions strong bullish, press conference packed, investors enthusiasm." Under the aura of intelligent medical care, nine health care has been attracting attention, since the end of last year, the shares of the Health Care Corporation have started to explode, rising from 10 yuan to a maximum of 27Yuan. However, from the current performance of nine health care, Ihealth series products have not made much contribution to the company's performance. In the 2013 report, nine health care did not disclose the Ihealth series of sales revenue, in the product classification also did not give ihealth separate explanation. Previously, the company also in the stock price of the notice pointed out that, as of 2013, the Ihealth series of business revenue accounted for the company's main business income is still relatively small, is still in the early stage of import, new product research and development investment, marketing costs larger. However, in the annual report, the company pointed out that since 2011, the company's annual 2~3 Ihealth series of new product speed, is now listed in the 5 categories, 10 balance related products, product measurable data basically covers the main indicators of personal health management.